DDrare: Database of Drug Development for Rare Diseases

Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ABC008; ARIMOCLOMOL; Alemtuzumab; Alemtuzumab (Campath); Anakinra; Arimoclomol; Arimoclomol citrate; BOTULINUM TOXIN TYPE A; BRX-345; BYM338; BYM338 (Bimagrumab); BYM338/bimagrumab; Bimagrumab; Botulinum toxin type A; Care as usual; Etanercept; FLEBOGAMMA 5%; Gamma Globulin; Immunoglobulins, normal human, for intravascular adm.; Natalizumab; Null; Other: Blood-flow restricted training; Phenylbutyrate; Phenylbutyrate Oral Tablet; Pioglitazone; RAAV1.CMV.huFollistatin344; REGN2477+REGN1033; Rapamycin; SIVASTIN; Simvastatin; Sivastin; Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01925209 (ClinicalTrials.gov)	September 26, 2013	15/8/2013	Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients	A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis	Sporadic Inclusion Body Myositis	Drug: BYM338/bimagrumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	36 Years	85 Years	All	251	Phase 2;Phase 3	United States;Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;Germany;Poland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01925209
(ClinicalTrials.gov)

September 26, 2013

15/8/2013

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis

Drug: BYM338/bimagrumab;Drug: Placebo

Novartis Pharmaceuticals

NULL

Completed

36 Years

85 Years

All

251

Phase 2;Phase 3

United States;Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;Germany;Poland